IRIS
ZANGHI', AURORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.306
EU - Europa 1.253
AS - Asia 1.108
SA - Sud America 283
AF - Africa 25
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.985
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.266
SG - Singapore 518
IE - Irlanda 385
RU - Federazione Russa 280
BR - Brasile 239
CN - Cina 196
IT - Italia 190
HK - Hong Kong 143
VN - Vietnam 106
FR - Francia 88
DE - Germania 78
SE - Svezia 71
FI - Finlandia 48
BD - Bangladesh 45
GB - Regno Unito 36
CA - Canada 22
AR - Argentina 17
IN - India 17
TR - Turchia 17
NL - Olanda 15
IQ - Iraq 11
PL - Polonia 11
MX - Messico 10
EC - Ecuador 8
AT - Austria 7
ES - Italia 7
ID - Indonesia 7
IR - Iran 7
ZA - Sudafrica 7
AU - Australia 6
JP - Giappone 6
PK - Pakistan 6
BE - Belgio 5
CL - Cile 5
EG - Egitto 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
MA - Marocco 4
SA - Arabia Saudita 4
VE - Venezuela 4
AL - Albania 3
CO - Colombia 3
DZ - Algeria 3
HU - Ungheria 3
PH - Filippine 3
PT - Portogallo 3
PY - Paraguay 3
RO - Romania 3
UZ - Uzbekistan 3
CI - Costa d'Avorio 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HN - Honduras 2
HR - Croazia 2
JO - Giordania 2
LT - Lituania 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
UA - Ucraina 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TO - Tonga 1
Totale 3.985
Salva come PNG Salva come JPEG
Città #
San Jose 424
Dublin 385
Singapore 197
Ashburn 145
Hong Kong 138
Beijing 102
Chandler 87
Santa Clara 72
Nyköping 70
Lauterbourg 59
Ho Chi Minh City 39
Princeton 39
Helsinki 34
Los Angeles 28
Munich 27
Wilmington 26
São Paulo 25
Dallas 22
Frankfurt am Main 21
Hanoi 19
Naples 19
Moscow 17
New York 16
Turku 14
London 13
Assago 12
Council Bluffs 11
Des Moines 11
Milan 11
Rome 11
Hillsboro 10
Rio de Janeiro 10
Warsaw 10
Nuremberg 9
Seattle 9
Falkenstein 8
Kocaeli 8
Chicago 7
Düsseldorf 7
Guangzhou 7
Bari 6
Belo Horizonte 6
Buffalo 6
Curitiba 6
San Francisco 6
Ankara 5
Biên Hòa 5
Frattamaggiore 5
Montreal 5
Ottawa 5
Paris 5
Tehran 5
The Dalles 5
Thái Bình 5
Tokyo 5
Toronto 5
Washington 5
Alessandria 4
Brooklyn 4
Cairo 4
Campinas 4
Cedar Knolls 4
Denver 4
Francavilla Fontana 4
Johannesburg 4
Long Beach 4
Ninh Bình 4
Orem 4
Reston 4
Ribeirão Preto 4
San Severo 4
Sorocaba 4
Tsuen Wan 4
Ufa 4
Vienna 4
Anápolis 3
Atlanta 3
Brussels 3
Buenos Aires 3
Bắc Ninh 3
Can Tho 3
Caxias do Sul 3
Chennai 3
Contagem 3
Da Nang 3
Guarulhos 3
Haiphong 3
Jiaxing 3
Karachi 3
Las Vegas 3
Lisbon 3
Lucera 3
Mexico City 3
New Haven 3
Norwalk 3
Phoenix 3
Porto Alegre 3
Quito 3
Riyadh 3
Shenzhen 3
Totale 2.416
Salva come PNG Salva come JPEG
Nome #
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 111
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 111
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 97
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 97
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 96
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 95
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 92
Can new chemical therapies improve the management of multiple sclerosis in children? 91
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 91
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 88
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 87
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 87
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 86
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 85
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 85
An update on the safety of treating relapsing-remitting multiple sclerosis 82
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 79
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 78
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 77
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 76
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 75
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 73
Management of dysphagia in multiple sclerosis: current best practice 73
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 70
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 69
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 69
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 66
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 66
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 66
Myeloid-derived Suppressor Cells and Multiple Sclerosis 65
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 65
Palliative care in progressive multiple sclerosis 64
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 64
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 63
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 61
A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles 60
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 60
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 60
Monocytic myeloid derived suppressor cells in hematological malignancies 58
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 56
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 55
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 55
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype 54
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 54
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 54
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 53
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 53
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 53
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 52
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 52
Multiple sclerosis from onset to secondary progression: a 30-year Italian register study 51
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 51
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study 51
Neural precursor cells tune striatal connectivity through the release of IGFBPL1 51
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 51
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 50
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 50
Real-world comparison of safety profile in two groups of relapsing remitting multiple sclerosis on dimethyl-fumarate and teriflunomide therapy: preliminary results of a multicenter, prospective study 48
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 47
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey 44
Pharmacoeconomics of synthetic therapies for multiple sclerosis 42
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 41
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series 41
New treatment targets in multiple sclerosis therapy 41
null 37
Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study 33
Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab 25
Cortical Atrophy and Cognitive Outcomes in Relapsing MS Patients Treated With Ofatumumab: a Real-World Longitudinal Study 15
null 12
null 8
null 8
Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion-informed capacity and service-flow analysis 3
Multidomain Fatigue, Cognitive, and Quality of Life Observations in Generalized Myasthenia Gravis Under Ravulizumab: A Case Series 2
Totale 4.431
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.975
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.975
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 0 1
2021/2022231 5 0 1 0 95 5 7 14 26 16 4 58
2022/2023722 60 18 39 47 14 44 2 37 413 19 17 12
2023/2024219 15 29 13 17 36 11 18 35 21 9 9 6
2024/20251.061 42 35 38 12 19 117 144 55 250 69 108 172
2025/20262.173 96 247 240 322 117 86 303 217 200 121 79 145
Totale 4.431